Regulation In this exclusive interview, Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), defines ‘fair pricing’, gives the IFPMA’s take on so-called “cost-plus” pricing models, and talks about access to medicine in developing markets.   The innovative pharmaceutical industry seems to be under unprecedented pressure…

Diversity Ai Hua Ong, Company Group Chairman, Asia Pacific, The Janssen Pharmaceutical Companies of Johnson & Johnson.   There is a clear correlation between an inclusive culture and innovation Creating a diverse workforce and an inclusive culture is key to an organisation’s success in today’s and tomorrow’s world. Organisations large and…

R&D In my career, I’ve held senior roles in both the biopharma and diagnostics sectors. Working across different cost structures, different business issues, and different regulatory systems in different parts of the world. I was once challenged as a new CEO in diagnostics by a pharma analyst to explain why I…

Cyprus Cyprus is capitalizing on its well-established tourism infrastructure to stake a claim for itself as one of Europe’s premier medical tourism destinations. “I believe Cyprus can become a really important hub for medical tourism thanks to our welcoming culture, great weather and educated talent pool.” Christoforos Hadjikyprianou, CEO of European…

Cannabis In a move to capitalize on a global market projected to exceed USD 60 billion by 2024, Cyprus has joined a growing number of European nations in legally permitting the cultivation and provision of medical cannabis.   The Republic will grant two 15-year licenses to private medical cannabis cultivators to…

Regulation Article contributed by Carla Smith, Executive Vice President of The Healthcare Information and Management Systems Society (HIMMS) for PharmaBoardroom. Today more Canadians are dying in this crisis than at the height of the HIV epidemic. Recognizing that we need to join forces to fight the opioid epidemics in both our nations, Canadians…

brexit Last week, Roche Boss Severin Schwan expressed concern that Brexit could further slow the UK drug approval process. After the UK’s recent divorce from the EMA, officials are in unknown territory. With only six months until the UK leaves the EU, the UK government has advised drug makers to stockpile…

Cancer Turkey has one of the most revered Social Security Systems in the world, providing its citizens with free healthcare and access to a long list of innovative cancer drugs. However, with one of the youngest populations in Europe, the sustainability of the system is uncertain as its incredibly young population gets older…

Brexit Despite a myriad of uncertainties around its decision to leave the European Union, the UK still stands as one of the world’s premier life science investment destinations. With heavyweight medical science infrastructure and a well-earned reputation for elite-level innovation, the key industry stakeholders featured in our UK report, explore how…

Innovation Yesterday, in their usual star-studded fanfare, Apple released two new products – one of which is set to be a major disruptor in the healthcare and life sciences industry. “It’s become an intelligent guardian for your health.” Jeff Williams, COO of Apple Apple events seem more like a rock concert…

Regulation It has been reported that in 2017 around 72,000 Americans died from drug overdoses, many from opiates. The company receiving the most attention is Purdue Pharma, run by the Sackler Family. Last week, the Financial Times launched multiple reports on the Sackler family and revealed a shocking story of manipulative sales tactics.  The…

Cannabis Founded in 1998, GW Pharmaceuticals is a true pioneer in cannabinoid medicines and the only pharmaceutical company with a license to cultivate cannabis in the UK. “While people were wary of cannabis, they became very aware that it was treating patients with severe conditions, where other medicines had either failed…